Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments

Reuters

2025/11/18

Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments

Protalix BioTherapeutics Inc. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, and initiating a multinational Phase 2 trial for PRX-115. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584876479"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584876479\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584876479?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584876479","market":"us","top_or_hot":-1,"title":"Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, and initiating a multinational Phase 2 trial for PRX-115. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-18 16:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLX\">Protalix BioTherapeutics Inc</a>. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, and initiating a multinational Phase 2 trial for PRX-115. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8VvndK:1","article_id":"2584876479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584876479","pubTimestamp":1763456200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protalix BioTherapeutics Inc. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLX":"Protalix BioTherapeutics Inc"},"translate_title":"Protalix BioTherapeutics展示罕见病治疗的管道进展和增长战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLX":0.9},"content_text":"Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments\n    \n\nProtalix BioTherapeutics Inc. has provided an update on its clinical and commercial pipeline. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from selling goods during the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash, with no debt or outstanding warrants, and anticipates becoming cash flow positive in the first half of 2027. The company's commercial portfolio includes approved enzyme replacement therapies for Fabry disease and Gaucher disease, with market presence in the US, EU, and additional regions. In its development pipeline, Protalix highlights PRX-115, a recombinant PEGylated uricase candidate for uncontrolled gout, with Phase 2 studies expected to begin in the fourth quarter of 2025. The company also reports ongoing research in rare renal diseases and other NETs-related diseases. Key upcoming milestones include expanding market share for existing products, pursuing additional geographic approvals, and initiating a multinational Phase 2 trial for PRX-115. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}